|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
56,200,000 |
Market
Cap: |
110.15(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.5 - $7.84 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 10.2 |
Insider 6 Months : 10.2 |
Insider 3/6 Months : 20.5 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
200,000 |
200,000 |
1,104,977 |
1,121,909 |
Total Buy Value |
$321,920 |
$321,920 |
$4,321,918 |
$4,427,874 |
Total People Bought |
2 |
2 |
3 |
4 |
Total Buy Transactions |
5 |
5 |
6 |
8 |
Total Shares Sold |
34,837 |
45,438 |
58,012 |
66,049 |
Total Sell Value |
$178,365 |
$230,844 |
$286,799 |
$318,236 |
Total People Sold |
1 |
2 |
2 |
3 |
Total Sell Transactions |
1 |
3 |
5 |
7 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Olson Eric R |
Chief Scientific Officer |
|
2020-08-17 |
4 |
AS |
$13.00 |
$64,519 |
D/D |
(4,963) |
0 |
|
- |
|
Olson Eric R |
Chief Scientific Officer |
|
2020-08-17 |
4 |
OE |
$1.01 |
$5,013 |
D/D |
4,963 |
4,963 |
|
- |
|
Young Richard A |
Director |
|
2020-08-17 |
4 |
AS |
$12.59 |
$75,414 |
D/D |
(5,990) |
347,181 |
|
- |
|
Young Richard A |
Director |
|
2020-07-15 |
4 |
AS |
$11.85 |
$70,982 |
D/D |
(5,990) |
353,171 |
|
- |
|
Olson Eric R |
Chief Scientific Officer |
|
2020-07-07 |
4 |
AS |
$11.72 |
$20,538 |
D/D |
(1,753) |
0 |
|
- |
|
Akkaraju Srinivas |
Director |
|
2020-07-01 |
4 |
AS |
$11.01 |
$50,966 |
I/I |
(4,627) |
1,433,943 |
|
- |
|
Akkaraju Srinivas |
Director |
|
2020-06-25 |
4 |
AS |
$11.15 |
$612,850 |
I/I |
(54,972) |
1,438,570 |
|
- |
|
Akkaraju Srinivas |
Director |
|
2020-06-24 |
4 |
AS |
$11.07 |
$539,788 |
I/I |
(48,775) |
1,493,542 |
|
- |
|
Akkaraju Srinivas |
Director |
|
2020-06-23 |
4 |
AS |
$11.11 |
$565,930 |
I/I |
(50,953) |
1,542,317 |
|
- |
|
Young Richard A |
Director |
|
2020-06-15 |
4 |
AS |
$8.75 |
$52,413 |
D/D |
(5,990) |
359,161 |
|
- |
|
Young Richard A |
Director |
|
2020-05-15 |
4 |
AS |
$9.22 |
$55,242 |
D/D |
(5,990) |
365,151 |
|
- |
|
Alles Mark J |
Director |
|
2020-05-13 |
4 |
B |
$8.86 |
$88,590 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
Young Richard A |
Director |
|
2020-04-15 |
4 |
AS |
$8.75 |
$209,650 |
D/D |
(23,960) |
371,141 |
|
- |
|
Olson Eric R |
Chief Scientific Officer |
|
2020-02-18 |
4 |
AS |
$7.38 |
$10,674 |
D/D |
(1,446) |
0 |
|
- |
|
Simonian Nancy A |
President & CEO |
|
2019-12-23 |
4 |
OE |
$3.04 |
$159,299 |
D/D |
52,401 |
533,689 |
|
- |
|
Springhorn Jeremy P. |
Chief Business Officer |
|
2019-11-12 |
4 |
AB |
$4.97 |
$50,268 |
D/D |
10,121 |
35,000 |
|
- |
|
Springhorn Jeremy P. |
Chief Business Officer |
|
2019-11-11 |
4 |
AB |
$4.99 |
$49,328 |
D/D |
9,879 |
24,879 |
|
- |
|
Young Richard A |
Director |
|
2019-08-16 |
4 |
AS |
$10.00 |
$227,000 |
D/D |
(22,700) |
395,101 |
|
- |
|
Young Richard A |
Director |
|
2019-08-15 |
4 |
AS |
$10.00 |
$23,000 |
D/D |
(2,300) |
417,801 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2019-07-17 |
4 |
S |
$7.70 |
$265,687 |
D/D |
(34,521) |
4,242,051 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2019-07-16 |
4 |
S |
$7.81 |
$201,277 |
D/D |
(25,779) |
4,276,572 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2019-07-15 |
4 |
S |
$8.27 |
$22,316 |
D/D |
(2,700) |
4,302,051 |
|
- |
|
Akkaraju Srinivas |
Director |
|
2019-04-09 |
4 |
B |
$7.50 |
$3,999,990 |
I/I |
533,332 |
1,593,270 |
2.1 |
- |
|
Nelsen Robert |
10% Owner |
|
2019-03-14 |
4 |
S |
$8.15 |
$350,441 |
D/D |
(43,000) |
4,305,051 |
|
- |
|
Nelsen Robert |
10% Owner |
|
2019-03-13 |
4 |
S |
$7.89 |
$666,565 |
D/D |
(84,411) |
4,348,051 |
|
- |
|
157 Records found
|
|
Page 4 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|